Core Insights - Noul Co., Ltd. has joined the NVIDIA Healthcare & Life Sciences ecosystem to enhance global diagnostic accessibility and seeks partnerships in global healthcare opportunities [1][2] - The company showcased its AI-powered diagnostic platform, miLab™ CER, at NVIDIA GTC 2025, focusing on cervical cancer screening [1][4] Company Overview - Noul Co., Ltd. is a medical AI company founded in December 2015, aiming to address global health challenges through innovative solutions [7] - The company has developed miLab™, the world's first AI-powered diagnostic lab platform for point-of-care settings, which automates the entire microscopy workflow [8][9] Product Features - miLab™ is a fully automated diagnostic solution that provides lab-grade accuracy and delivers results in under 15 minutes, utilizing deep learning and AI for analysis [4][8] - The platform is powered by NVIDIA Jetson, enhancing AI inference performance and supporting scalable diagnostics across various diseases [4] Recognition and Impact - Noul's cervical cancer solution, miLab™ CER, was recognized by WHO-UNITAID in 2024 as one of the Top 3 global diagnostic products [5][9] - The company aims to positively influence the lives of over 1 billion people worldwide, particularly in blood and cancer diagnostics [11] Market Presence - miLab is currently utilized in 18 countries by pharmaceutical companies, hospitals, diagnostic labs, and government health institutions, indicating a strong global presence [10]